HbA1c News and Research

RSS

Coordinated care approach to diabetes self-management benefits underserved adult populations

Even in communities with barriers to health care, exercise opportunities and healthy food, residents with diabetes saw improved health outcomes when they participated in programs that took a coordinated care approach to diabetes self-management.

12 Jan 2016

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in their efficacy and safety profiles, according to new research by the University of Leicester.

10 Dec 2015

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes.

9 Dec 2015

Combining two blood sugar tests may improve prediabetes detection, study finds

Using a combination of two blood sugar tests rather than a single test would improve detection of prediabetes in American children and adults, according to a new study by researchers at the School of Public Health at Georgia State University.

1 Dec 2015

Testosterone treatment can benefit men with Type 2 diabetes

Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment.

30 Nov 2015

Structured personal diabetes care improves outcomes in women

A follow-up study to assess the effects of personally tailored diabetes care in general practice has revealed that such care reduces mortality (both all-cause and diabetes-related), in women, but not men. The study is by Dr Marlene Krag, The Research Unit for General Practice, Department of Public Health, University of Copenhagen, Denmark, and colleagues, and is published in Diabetologia, the journal of the European Association for the Study of Diabetes.

27 Nov 2015

New clinical chemistry analyzer launched by EKF at Medica 2015

EKF, launched the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.

From EKF Diagnostics 10 Nov 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF, announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham.

From EKF Diagnostics 24 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

Smoking prevalence remains same but proportion of smokers with no intention of quitting increases

Smoking prevalence has stayed the same but the proportion with no intention of quitting has risen in the last seven years, according to results from the latest EUROASPIRE surveys presented for the first time today at ESC Congress 2015 by Professor Kornelia Kotseva, chair of the EUROASPIRE Steering Committee and senior clinical research fellow at Imperial College London, UK.

2 Sep 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

New Tel Aviv University study reveals impact of skipping breakfast on the health of diabetics

More and more Americans on-the-go are skipping the "most important meal of the day," not eating until lunch. This tendency to miss breakfast has already been linked to the growing epidemic of obesity and cardiovascular problems in the US -- and it may put the health of diabetics at risk as well.

29 Jul 2015

EKF Diagnostics launches new clinical chemistry analyzer at AACC 2015

EKF, announces international launch of the Altair™ 240 clinical chemistry analyzer at the American Association for Clinical Chemistry’s.

From EKF Diagnostics 23 Jul 2015

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms.

26 Jun 2015

Roche unveils series of new diagnostic technologies at EuroMedLab

Today at the 21st annual meeting of the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Paris, France, Roche unveiled a series of new diagnostic technologies.

23 Jun 2015

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood.

From Ortho-Clinical Diagnostics, Inc. 22 Jun 2015

Sebia’s Capillarys 3 Tera automated electrophoresis solution receives CE mark

Sebia, the world leader in capillary electrophoresis, today announces that Capillarys 3 Tera now has the CE mark for HbA1c and serum protein testing, and immunotyping. The CE mark for these tests is the first step in bringing the Capillarys 3 suite to market.

12 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015